小议供应链中的“牛鞭效应”

阐述了牛鞭效应的含义,指出了牛鞭效应的危害,分析了产生牛鞭效应的原因．提出了减缓牛鞭效应的办法。     

AN AUTOMATED REFERENCE POINT-LIKE APPROACH FOR MULTICRITERIA SHORTEST PATH PROBLEMS

1. Introduction Nowadays the exponential and convergent development of informatics and telecommunications, including Internet, makes that, in many communication networks, important decisions of technical nature have to be made in short time periods or even in real-time. This is particularly relevant in the context of routing models involving the calculation and selection of routes (corresponding to loopless paths) for node to node traffic flows, which seek to optimize certain metric(s) while s…     

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Bacterial infection remains a serious threat to human lives because of emerging resistance to existing antibiotics. Although the scientific community has avidly pursued the discovery of new antibiotics that interact with new targets, these efforts have met with limited success since the early 1960s. Here we report the discovery of platensimycin, a previously unknown class of antibiotics produced by Streptomyces platensis. Platensimycin demonstrates strong, broad-spectrum Gram-positive antibacterial activity by selectively inhibiting cellular lipid biosynthesis. We show that this anti-bacterial effect is exerted through the selective targeting of beta-ketoacyl-(acyl-carrier-protein (ACP)) synthase I/II (FabF/B) in the synthetic pathway of fatty acids. Direct binding assays show that platensimycin interacts specifically with the acyl-enzyme intermediate of the target protein, and X-ray crystallographic studies reveal that a specific conformational change that occurs on acylation must take place before the inhibitor can bind. Treatment with platensimycin eradicates Staphylococcus aureus infection in mice. Because of its unique mode of action, platensimycin shows no cross-resistance to other key antibiotic-resistant strains tested, including methicillin-resistant S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant enterococci. Platensimycin is the most potent inhibitor reported for the FabF/B condensing enzymes, and is the only inhibitor of these targets that shows broad-spectrum activity, in vivo efficacy and no observed toxicity.